


Timosaponin BII Datasheet

4th Edition (Revised in July, 2016)**[Product Information]****Name:** Timosaponin BII**Catalog No.:** CFN98150**Cas No.:** 136656-07-0**Purity:** >=98%**M.F:** C₄₅H₇₆O₁₉**M.W:** 920.08**Physical Description:** Powder**Synonyms:** (25S)-26-(β-D-Glucopyranosyloxy)-3β-[(2-O-β-D-glucopyranosyl-β-D-galactopyranosyl)oxy]-5β-furostan-22-ol.**[Intended Use]**

1. Reference standards;
2. Pharmacological research;
3. Synthetic precursor compounds;
4. Intermediates & Fine Chemicals;
5. Others.

[Source]The rhizomes of *Anemarrhena asphodeloides* Bunge.**[Biological Activity or Inhibitors]**

Timosaponin-BII, a purified extract originating from Chinese medical herb *Rhizoma Anemarrhenae*, is characterized as an antioxidant, it can remarkably inhibit the up-regulation of β -amyloid precursor protein cleavage enzyme-1 (BACE1) and reduced the over-production of β -CTF and A β in rat retina, which was induced by FeCl₃, the mechanism of timosaponin-BII on BACE1 expression may be related to its antioxidant property. ^[1]

Timosaponin BII can improve the neurological symptoms of cerebral ischemic rat, reduce infarct size, relieve brain water edema, improve hemorheology, reduce inflammatory injury of cerebral ischemia; it could be used in the preparation of a medicament or product for the prevention and treatment of stroke. ^[2]

Timosaponin BII can significantly reduce the neurotoxicity induced by beta amyloid peptide 25-35 in primary neurons, the mechanism of which may be related with resisting oxidative damage and regulating the cholinergic system. ^[3]

[Solvent]

Pyridine, Methanol, Ethanol, etc.

[HPLC Method]^[4]

HPLC-CAD

Mobile phase: Acetonitrile- H₂O=25:75;

Flow rate: 1.0 ml/min;

Column temperature: 30 °C;

Carrier gas: N₂;

Pressure of gas:241.3 kPa.

[Storage]

2-8°C, Protected from air and light, refrigerate or freeze.

[References]

- [1] Huang J F, Shang L, Liu P, *et al.* *Bmc Complem. Altern. M.*, 2012, 12(1):1-8.
- [2] Ma B, Xu Q, Zhao Y, *et al.* , *US20090075912[P]*. 2009.
- [3] Deng Y, Ma B P, Cong Y W, *et al.* *Chinese Pharmacological Bulletin*, 2009, 25(2):244-7.
- [4] Wu Y, Gao H, Song Z B, *et al.* *Drugs & Clinic*, 2014, 29(7):737-41.

[Contact]

Address:

S5-3 Building, No. 111, Dongfeng Rd.,
Wuhan Economic and Technological Development Zone,
Wuhan, Hubei 430056,
China

Email: info@chemfaces.com

Tel: +86-27-84237783

Fax: +86-27-84254680

Web: www.chemfaces.com

Tech Support: service@chemfaces.com